We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation,treated with olaparib monotherapy.The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma...We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation,treated with olaparib monotherapy.The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy,cytoreductive surgery,and postoperative chemotherapy.After a second cancer recurrence,she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy.Based on the FoundationOne CDx results,olaparib monotherapy was started.After 13 months of therapy,all lesions responded to the treatment,and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography(PET-CT).We plan to continue olaparib monotherapy until disease progression.展开更多
REV1是跨损伤聚合酶Y家族的重要成员之一,它不仅作为支架蛋白介导Y家族聚合酶招募至损伤位点完成跨损伤DNA合成(translesion DNA synthesis, TLS),还可利用自身的dCMP转移酶活性在一些损伤位点对侧整合dCMP参与TLS。此外,REV1也被报导...REV1是跨损伤聚合酶Y家族的重要成员之一,它不仅作为支架蛋白介导Y家族聚合酶招募至损伤位点完成跨损伤DNA合成(translesion DNA synthesis, TLS),还可利用自身的dCMP转移酶活性在一些损伤位点对侧整合dCMP参与TLS。此外,REV1也被报导参与调控同源重组修复。为进一步探讨REV1互作蛋白RAD51和RAD51C在其参与的同源重组修复通路中的调控作用,本研究采用脉冲氮激光微辐射实验,发现RAD51可调控REV1到双链断裂位点的募集。同时,免疫荧光实验结果证明REV1也反过来影响RAD51应答CPT损伤。然而敲低RAD51C并不影响REV1到DNA双链断裂位点的招募。结果表明,REV1和RAD51在HR通路中存在彼此相互调控的关系。展开更多
文摘We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation,treated with olaparib monotherapy.The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy,cytoreductive surgery,and postoperative chemotherapy.After a second cancer recurrence,she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy.Based on the FoundationOne CDx results,olaparib monotherapy was started.After 13 months of therapy,all lesions responded to the treatment,and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography(PET-CT).We plan to continue olaparib monotherapy until disease progression.
文摘REV1是跨损伤聚合酶Y家族的重要成员之一,它不仅作为支架蛋白介导Y家族聚合酶招募至损伤位点完成跨损伤DNA合成(translesion DNA synthesis, TLS),还可利用自身的dCMP转移酶活性在一些损伤位点对侧整合dCMP参与TLS。此外,REV1也被报导参与调控同源重组修复。为进一步探讨REV1互作蛋白RAD51和RAD51C在其参与的同源重组修复通路中的调控作用,本研究采用脉冲氮激光微辐射实验,发现RAD51可调控REV1到双链断裂位点的募集。同时,免疫荧光实验结果证明REV1也反过来影响RAD51应答CPT损伤。然而敲低RAD51C并不影响REV1到DNA双链断裂位点的招募。结果表明,REV1和RAD51在HR通路中存在彼此相互调控的关系。
